Project HERCULES team

Project HERCULES is led by Duchenne UK.

Its Steering Group is chaired by Fleur Chandler, Head of Market Access at Sanofi, whose son Dominic has Duchenne muscular dystrophy (DMD).

The Project Director is Josie Godfrey, who led work to establish the UK’s Health Technology Assessment programme for rare diseases at the National Institute for Health and Care Excellence (NICE).

The Project HERCULES Steering Group is the decision-making body which oversees the delivery of the objectives of Project HERCULES. The group meets twice a year. It is comprised of the Project HERCULES team members and the following companies, patient groups, advisors and vendors.


Members include representatives from:

  • Astellas Pharma Inc
  • Catabasis Pharmaceuticals Inc
  • Pfizer Inc
  • PTC Therapeutics International Limited,
  • Roche
  • Sarepta Therapeutics Inc
  • Solid Biosciences LLC
  • Santhera Pharmaceuticals Holding AG
  • Wave Life Sciences USA


Patient groups

Members include representatives from:

  • PPMD (US)
  • World Duchenne Organisation (UPPMD)
  • Save Our Sons (Australia)
  • Stand For Duchenne Canada
  • Jesse’s Journey (Canada)


  • Prof Ron Akehurst, BresMed
  • Meriem Bouslouk, Independent German HTA expert
  • Merce Obach Cortadellas, Catsalut
  • Prof Jalpa Doshi, University of Pennsylvania
  • Karen Facey, University of Edinburgh
  • Dr Michela Guglieri, Newcastle University
  • Anthony Hatswell, Delta Hat
  • Jane Larkindale, C-Path (US)
  • Dr Anna Sarkozy, GOSH London
  • Juliana Setyawan, US
  • James Signorovitch and Susan Ward, cTAP (US)  
  • Ian Watson, NICE  
  • Dr Jarod Wong, University of Glasgow



Vendors also attend the Steering Group:

  • Aparito
  • HCD Economics
  • Oxford University Innovation
  • Pharmatelligence
  • Sheffield School of Health and Related Research (ScHARR)
  • Source HEOR
  • Tolley Health Economics
  • University of Leicester